Monday, 23 May 2022

Bharat Biotech's Covaxin receives EUA for 12-18 years old

27 December 2021 | News

Covaxin is formulated uniquely such that the same dosage can be administered to adults and children

image credit- Bharat Biotech

image credit- Bharat Biotech

Hyderabad-based Bharat Biotech’s COVID-19 vaccine Covaxin has received the emergency use authorization (EUA) for children of age group 12 to 18 years.

Covaxin has established a proven record for safety and efficacy in adults for the original variant and subsequent variants.

The company has documented excellent safety and immunogenicity data readouts in children.

Bharat Biotech is expecting for COVAXIN to provide similar levels of protection for adults and children alike.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account